Patient & Community Webinar Series

We are committed to an ongoing dialogue about the HEALEY ALS Platform Trial with the entire ALS patient community.

We will continue to share enrollment updates as well as new ideas and opportunities, and will be available to answer any and all questions that the community might have about this groundbreaking trial.

We will host webinars on a monthly basis for comprehensive updates and host weekly informal Q&A sessions. The idea of weekly interactive sessions came from our Patient Advisory Committee and we absolutely love the opportunity to connect with all who might be interested on a frequent basis. Please join us as often as you would like: our investigators and study team are available to discuss your questions.

To submit questions prior to the webinars please email healeyalsplatform@mgh.harvard.edu

Upcoming Webinars

Previous News

October 21: ALS/MND Alliance Clinical Trial Design Webinar
Merit Cudkowicz, MD, MSc joined researchers from from Europe and Scotland to discuss new research and clinical trial models, how they will change the landscape going forward and their practical implications for patients and researchers. Watch recording.

October 13: CTTI Master Protocol Development Webinar for Researchers
Marianne Chase, the Senior Director Clinical Trial Operations at Mass General's Neurological Clinical Research Institute, joined representatives from the FDA, Janssen R&D and Edgewise Therapeutics to discuss the design of master protocol clinical trials, which allow researchers to answer multiple scientific questions within a single trial. Watch recording.

September 29, 2020: Monthly Update Webinar
Merit Cudkowicz, MD, MSc, principal investigator, and Sabrina Paganoni, MD, co-principal investigator of the HEALEY ALS Platform Trial, provided an update on the progress of the HEALEY ALS Platform Trial. They were joined by Kuldip Dave, PhD, of the ALS Association.
Watch recording

August 27, 2020: Monthly Update Webinar
Sabrina Paganoni, MD, co-principal investigator of the HEALEY ALS Platform Trial, joined Taner Dagdelen, co-founder and CEO of Unite Genomics, for a webinar on August 27 to discuss the latest updates on the trial.
Watch recording.

August 3, 2020: Sites Begin Opening for Enrollment
Enrollment has started in the HEALEY ALS Platform Trial at selected sites, and we expect to add more sites and more potential therapies soon.

Read the full announcement     See list of sites

Watch Our Launch Video

July 7, 2020: Status Update
Healey Center faculty provide update on the status of the HEALEY ALS Platform Trial.
Watch recording.

March 25, 2020: COVID Updates and April 8th Webinar
As you all are, we too are closely monitoring the impact of COVID-19 on the HEALEY ALS Platform Trial timelines and operations.  The bottom line is this: we are committed to beginning the trial as soon and as safely as we can.

January 22, 2020: Sean M. Healey & AMG Center for ALS at Mass General receives “May Proceed” notice for three drugs in first ALS platform trial
The Sean M. Healey & AMG Center for ALS at Mass General has received approval from the U.S. Food and Drug Administration (FDA) to proceed with administering three proposed drug regimens in the HEALEY ALS Platform Trial – the first trial of its kind for amyotrophic lateral sclerosis (ALS)

Merit Cudkowicz, MD, MSc, Director of the Healey Center for ALS, discusses the impact of the “May Proceed” notice from the FDA for three drugs in first ALS platform trial

January 14, 2020: ALS Association makes multi-year commitment to HEALEY ALS Platform Trial
The ALS Association announced a $3 million commitment to the first platform trial for ALS, taking place at the Sean M. Healey & AMG Center for ALS at Mass General in collaboration with the Barrow Neurological Institute and the Northeast ALS Consortium (NEALS).

September 18, 2019: Sean M. Healey & AMG Center for ALS at Mass General launches first ALS Platform Trial with 5 promising drugs
The Sean M. Healey & AMG Center at Massachusetts General Hospital will launch the first platform trial for amyotrophic lateral sclerosis (ALS) to accelerate the development of effective and breakthrough treatments for people with ALS.